Publications by authors named "Mark Karwal"

Claim this Profile
H
Hyperammonemic Encephalopathy in Fibrolamellar Hepatocellular Carcinoma: A Case of Rapid Neurologic Recovery Following Cytoreductive Surgery.
Robert Schoeneich, Udhayvir S Grewal, Tanner J Simonson, Bohae R Lee, Rishi R Patel, Mark W Karwal

J Clin Exp Hepatol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial.
Gontran Verset, Ivan Borbath, Mark Karwal, Chris Verslype, Hans Van Vlierberghe

Clin Cancer Res· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Understanding the patient experience in hepatocellular carcinoma: a qualitative patient interview study.
Nikunj Patel, Joshua Maher, Xandra Lie, Chad Gwaltney, Afsaneh Barzi, Mark Karwal

Qual Life Res· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology.
Peter R Galle, Masatoshi Kudo, Josep M Llovet, Richard S Finn, Mark Karwal

Liver Int· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Pilot Study of Preoperative Vandetanib on Markers of Proliferation and Apoptosis in Breast Cancer.
Philip M Spanheimer, Amani Bashir, Allison W Lorenzen, Anna C Beck, Junlin Liao, Mark W Karwal

Am J Clin Oncol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Performing thermal ablations for hepatomas - is it a worthy skill for hepatologists?
Tomohiro Tanaka, Divya Ashat, Shiliang Sun, Sandeep Laroia, Mark Karwal

Ann Hepatol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: a pooled subset analysis of two phase III studies.
Jacek Jassem, Luis Fein, Mark Karwal, Mario Campone, Ronald Peck

Breast· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durable responses to rituximab in acquired factor VIII deficiency.
Abha G Singh, Iyad S Hamarneh, Mark W Karwal, Steven R Lentz

Thromb Haemost· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma.
Joong-Won Park, Richard S Finn, Jun Suk Kim, Mark Karwal, Ruby K Li

Clin Cancer Res· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice-daily regimen to treat patients with recurrent metastatic breast cancer.
Gabriel N Hortobagyi, Robyn R Young, Mark Karwal, Nuhad K Ibrahim, Robert Hermann

Cancer· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hemolysis and elevated transaminases imitating severe preeclampsia.
Bridget Kamen, Mark A Karwal, Jerome Yankowitz

Obstet Gynecol· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tracheobronchial amyloidosis: a surgical disease with long-term consequences.
Kevin A Dahl, Kemp H Kernstine, Timothy L Vannatta, Mark W Karwal, Karl W Thomas

J Thorac Cardiovasc Surg· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment.
David Bushnell, Yusuf Menda, Thomas O'Dorisio, Mark Madsen, Sara Miller, Mark Karwal

Cancer Biother Radiopharm· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors.
David Bushnell, Thomas O'Dorisio, Yusuf Menda, Thomas Carlisle, Pamela Zehr, Mark Karwal

J Nucl Med· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of hepatic toxicity from treatment with 90Y-SMT 487 (OctreoTher(TM)) in patients with diffuse somatostatin receptor positive liver metastases.
David Bushnell, Yusuf Menda, Mark Madsen, Thomas O'Dorisio, Thomas Carlisle, Mark Karwal

Cancer Biother Radiopharm· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis